

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):


- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

In the Claims:

1. (Currently Amended) A compound having a general formula (II):



[II]

wherein R_1 is ~~a~~ an unsaturated alkyl, amino alcohol, diamine, or cycloalkyl; with
 R_Q and R_T are each independently selected from the group consisting of a hydrogen,
 halogen, a hydroxyl, a saturated, unsaturated, aliphatic, or branched, alkyl, a substituted or
 unsubstituted $(CH_2)_m$ -(hetero)aryl, ~~and a sulfonylamide, and a pharmaceutically acceptable~~
~~salt thereof;~~ q and t are each an integer independently selected from 1-4; and
~~pharmaceutically acceptable salts thereof or wherein R_1 is an amino-alcohol being~~
 ~~$(CH_2)_nCHOHCH_2NR'R''$ with q and t each an integer independently selected from 1-4,~~
~~wherein for n being 0 or 1, R' , R_Q , R_T , are each a hydrogen and R'' is selected from the~~
~~group consisting of a branched alkyl, a substituted or unsubstituted $(CH_2)_m$ -(hetero)aryl, a~~
~~sulfonylamide, and a pharmaceutically acceptable salt thereof, and wherein for n being 2 -~~
~~5, R' , R_Q , R_T , are each a hydrogen and R'' is selected from the group consisting of a~~
~~hydrogen, a halogen, a hydroxyl, a saturated, unsaturated, aliphatic, or branched, alkyl, a~~
~~substituted or unsubstituted $(CH_2)_m$ -(hetero)aryl, a sulfonylamide, and a pharmaceutically~~
~~acceptable salt thereof.~~


2. (Cancelled).

3. (Currently Amended) The compound of claim 21, wherein n is 2 and R'' is
 an alkyl selected from the group consisting of propyl, *n*-butyl, *tert*-butyl and with the
 proviso that R'' is not a methyl or an ethyl moiety.

4. (Currently Amended) The compound of claim 21, wherein n is 1 or 2 and R'' is saturated or unsaturated $(CH_2)_m$ -cycloalkyl or $(CH_2)_m$ -(hetero)aryl, m being 0-5.

5. (Original) The compound of claim 4, wherein m is 1 and R'' is an aromatic 6-member ring.

6. (Currently Amended) A composition for treating ~~or preventing~~ cardiac arrhythmia, comprising a pharmaceutically effective amount of a compound in combination with a pharmaceutically acceptable carrier selected from the group consisting of a slow release carrier, an implant and a transdermal patch, said compound being a member of a group having the formula:




wherein,

A is CH_2 , ~~CH_2~~ , $CH_2R_2R_3$, or $C=O$; B is CH , $CH_2R_4R_5$ or NR_6 , wherein R_2 , R_3 , R_4 , R_5 and R_6 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted $(CH_2)_m$ -(hetero)aryl; or A and B together are $C=C$; R_1 is an unsaturated alkyl, amino-alcohol, ~~diamino~~, cycloalkyl, and $C(=O)(CH_2)_nNR'R''$, $(CH_2)_nCHOHCH_2NR'R''$, wherein n is an integer being 0 - 5; R_Q , R_T , R' , and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted $(CH_2)_m$ -(hetero)aryl, and sulfonylamide; q and t are each an integer independently selected from 1-4; and pharmaceutically acceptable salts thereof.

7. (Original) The composition of claim 6, wherein A and B are each a carbon, R_2 , R_3 , R_4 and R_5 are each a hydrogen, and R_1 is $C(=O)(CH_2)_nNR'R''$, n being 0-5, R' and R are each hydrogen and R'' is as defined above.

8. (Original) The composition of claim 7, wherein n is 1 or 2 and R'' is an alkyl selected from the group consisting of methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, and *tert*-butyl.
9. (Original) The composition of claim 7, wherein n is 1 or 2 and R'' is saturated or unsaturated $(CH_2)_m$ -cycloalkyl or $(CH_2)_m$ -(hetero)aryl, m being 0-5.
10. (Original) The composition of claim 9, wherein m is 1 and R'' is an aromatic 6-member ring.
11. (Cancelled).
12. (Original) The composition of claim 11, wherein n is 2 and R'' is an alkyl selected from the group consisting of ethyl, propyl, *n*-butyl, *iso*-butyl, *tert*-butyl and *sec*-butyl.
13. (Original) The composition of claim 11, wherein n is 2 and R'' is saturated or unsaturated $(CH_2)_m$ -(hetero)aryl, m being 0-5.
14. (Currently Amended) A method for treating ~~or preventing~~ cardiac arrhythmia in a subject, the method comprising the step of administering a pharmaceutically effective amount of a compound, said compound being a member of a group having the formula:



wherein,

A is CH , CH_2 , CR_2R_3 , or $C=O$; B is CH , CR_4R_5 , or NR_6 , wherein R_2 , R_3 , R_4 , R_5 and R_6 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted

$(CH_2)_m$ -(hetero)aryl; or A and B together are $C=C$; R_1 is an unsaturated alkyl, amino-alcohol, ~~diamine~~, cycloalkyl, and $C(=O)(CH_2)_nNR'R''$, $(CH_2)_nCHOHCH_2NR'R''$, wherein n is an integer being 0-5; R_Q , R_T , R' , and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted $(CH_2)_m$ -(hetero)aryl, and sulfonylamide; q and t are each an integer independently selected from 1-4; and pharmaceutically acceptable salts thereof.

15. (Original) The method of claim 14, wherein A and B are each a CH moiety, R_2 , R_3 , R_4 and R_5 are each a hydrogen, and R_1 is $C(=O)(CH_2)_nNR'R''$, n being 0-5, R and R' are each hydrogen and R'' is as defined above.

16. (Original) The method of claim 14, wherein n is 2 and R'' is an alkyl selected from the group consisting of methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, *iso*-butyl, *tert*-butyl and *sec*-butyl.

17. (Original) The method of claim 15, wherein n is 2 and R'' is saturated or unsaturated $(CH_2)_m$ -(hetero)aryl, m being 0-5.

18. (Cancelled).


19. (Original) The method of claim 18, wherein n is 2 and R'' is an alkyl selected from the group consisting of methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, and *tert*-butyl.

20. (Original) The method of claim 18, wherein n is 2 and R'' is saturated or unsaturated $(CH_2)_m$ -(hetero)aryl, m being 0-5.

21. (Original) The method of claim 15, wherein said compound is administered to the subject parenterally.

22. (Original) The method of claim 15, wherein an implanted defibrillator is implanted in the subject, such that said compound is an adjunct treatment to defibrillation by said implanted defibrillator.

23. (Currently Amended) A method for ~~transforming sustained~~ treating ventricular fibrillation to ~~spontaneously defibrillating transient ventricular fibrillation~~ in a subject, the method comprising the step of administering a pharmaceutically effective amount of a compound, said compound being a member of a group having the formula:



wherein,


A is CH_2 or CR_2R_3 or $\text{C}=\text{O}$; B is CH , CR_4R_5 or NR_6 , wherein R_2 , R_3 , R_4 , R_5 and R_6 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted $(\text{CH}_2)_m$ -(hetero)aryl; or A and B together are $\text{C}=\text{C}$; R_1 is saturated or unsaturated alkyl, amino-alcohol, diamine, cycloalkyl, and $\text{C}(=\text{O})(\text{CH}_2)_n\text{NR}'\text{R}''$, $(\text{CH}_2)_n\text{CHOHCH}_2\text{NR}'\text{R}''$, wherein n is an integer being 0 - 5; R_Q , R_T , R' , and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted $(\text{CH}_2)_m$ -(hetero)aryl, and sulfonylamide; q and t are each an integer independently selected from 1-4; and pharmaceutically acceptable salts thereof.

24. (Original) The method of claim 23, wherein A and B are each a CH moiety, R_2 , R_3 , R_4 and R_5 are each a hydrogen, and R_1 is $\text{C}(=\text{O})(\text{CH}_2)_n\text{NR}'\text{R}''$, n being 0-5, R and R' are each hydrogen and R'' is as defined above.

25. (Original) The method of claim 24, wherein n is 2 and R'' is an alkyl selected from the group consisting of methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, and *tert*-butyl.

26. (Original) The method of claim 24, wherein n is 2 and R'' is saturated or unsaturated $(\text{CH}_2)_m$ -(hetero)aryl, m being 0-5.

27. (Currently Amended) The method of claim 23, wherein A is CR_2R_3 or $\text{C}=\text{O}$ and B is CR_4R_5 ; R_2 , R_3 , R_4 , R_5 and R_6 are each a hydrogen, and R_1 is $\text{C}(=\text{O})(\text{CH}_2)_n\text{NR}'\text{R}''$, n being 0-5 and R' is a hydrogen and R'' is as defined above.
28. (Original) The method of claim 27, wherein n is 2 and R'' is an alkyl selected from the group consisting of ethyl, propyl, *n*-butyl, *iso*-butyl, *tert*-butyl and *sec*-butyl.
29. (Original) The method of claim 27, wherein n is 2 and R'' is saturated or unsaturated $(\text{CH}_2)_m$ -(hetero)aryl, m being 0-5.
30. (Original) The method of claim 23, wherein said compound is administered to the subject parenterally.
31. (Original) The method of claim 23, wherein an implanted defibrillator is implanted in the subject, such that said compound is an adjunct treatment to defibrillation by said implanted defibrillator.
32. (Currently Amended) A method of ~~locally treating or preventing cardiac ischemia in a subject comprising the step of locally applying onto a cardiac tissue~~ administering to the subject a composition comprising a pharmaceutically effective amount of a compound in combination with a pharmaceutically acceptable carrier, said compound being a member of a group having the formula:




wherein A is CH_2 or CR_2R_3 or $\text{C}=\text{O}$; B is CH , CR_4R_5 or NR_6 , wherein R_2 , R_3 , R_4 , R_5 and R_6 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted $(\text{CH}_2)_m$ -(hetero)aryl; or A and B together are $\text{C}=\text{C}$; R_1 is saturated or

unsaturated alkyl, amino-alcohol, ~~diamino~~-cycloalkyl, and $C(=O)(CH_2)_nNR'R''$, $(CH_2)_nCHOHCH_2NR'R''$, wherein n is an integer being 0 - 5; R_Q , R_T , R' , and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted $(CH_2)_m$ -(hetero)aryl, and sulfonylamide; q and t are each an integer independently selected from 1-4; and pharmaceutically acceptable salts thereof.

33. (Currently Amended) The method of claim 32, wherein the step of ~~locally applying the~~administering said composition ~~onto said tissue to the subject~~ further comprises the steps of:

- (i) applying the composition to an implant; and
- (ii) inserting said implant into ~~said~~a tissue of the subject.

34. (Currently Amended) A method for transforming sustained ventricular fibrillation to spontaneously defibrillating transient ventricular fibrillation in a subject, the method comprising the step of inducing cardiac sympathetic activity by administering a compound to the subject, said compound being a member of a group having the formula:



wherein,

A is CH_2 or CR_2R_3 or $C=O$; B is CH , CR_4R_5 or NR_6 , wherein R_2 , R_3 , R_4 , R_5 and R_6 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted $(CH_2)_m$ -(hetero)aryl; or A and B together are $C=C$; R_1 is saturated or unsaturated alkyl, amino-alcohol, ~~diamino~~-cycloalkyl, and $C(=O)(CH_2)_nNR'R''$, $(CH_2)_nCHOHCH_2NR'R''$, wherein n is an integer being 0 - 5; R_Q , R_T , R' , and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted $(CH_2)_m$ -(hetero)aryl, and sulfonylamide; q and t are each an integer independently selected from 1-4; and pharmaceutically acceptable salts thereof.

35. (Original) The method of claim 34, wherein A and B are each a CH moiety, R_2 , R_3 , R_4 and R_5 are each a hydrogen, and R_1 is $C(=O)(CH_2)_nNR'R''$, n being 0-5 and R and R' are each hydrogen and R'' is as defined above.

36. (Original) The method of claim 35, wherein n is 2 and R'' is an alkyl selected from the group consisting of methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, *iso*-butyl, *tert*-butyl and *sec*-butyl.

37. (Original) The method of claim 35, wherein n is 2 and R'' is saturated or unsaturated $(CH_2)_m$ -(hetero)aryl, m being 0-5.

38. (Currently Amended) The method of claim 34, wherein A is CR_2R_3 or $C\equiv O$ and B is CR_4R_5 ; R_2 , R_3 , R_4 , R_5 and R_6 are each a hydrogen, and R_1 is $C(=O)(CH_2)_nNR'R''$, n being 0-5 and R' is a hydrogen and R'' is as defined above.

39. (Original) The method of claim 38, wherein n is 2 and R'' is an alkyl selected from the group consisting of methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, and *tert*-butyl.

40. (Original) The method of claim 38, wherein n is 2 and R'' is saturated or unsaturated $(CH_2)_m$ -(hetero)aryl, m being 0-5.

41. (New) The compound of claim 1, wherein said R1 is in a form selected from the group consisting of an R enantiomeric form, an S enantiomeric form, and a racemic mixture thereof.

42. (New) The composition of claim 6, wherein said R1 is in a form selected from the group consisting of an R enantiomeric form, an S enantiomeric form, and a racemic mixture thereof.

43. (New) The method of claim 14, wherein said R1 is in a form selected from the group consisting of an R enantiomeric form, an S enantiomeric form, and a racemic mixture thereof.

44. (New) The method of claim 23, wherein said R1 is in a form selected from the group consisting of an R enantiomeric form, an S enantiomeric form, and a racemic mixture thereof.

45. (New) The method of claim 32, wherein said R1 is in a form selected from the group consisting of an R enantiomeric form, an S enantiomeric form, and a racemic mixture thereof.

46. (New) The method of claim 34, wherein said R1 is in a form selected from the group consisting of an R enantiomeric form, an S enantiomeric form, and a racemic mixture thereof.